<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:chebi fb="0" ids="52726">proteasome inhibitors</z:chebi> are a new class of antitumor agents </plain></SENT>
<SENT sid="1" pm="."><plain>These inhibitors cause the accumulation of many proteins in the cell with the induction of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> including TRAIL <z:hpo ids='HP_0011420'>death</z:hpo> receptors DR4 and DR5, but the role of the TRAIL apoptotic pathway in <z:chebi fb="0" ids="52726">proteasome inhibitor</z:chebi> cytotoxicity is unknown </plain></SENT>
<SENT sid="2" pm="."><plain>Herein, we have demonstrated that the induction of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> by the <z:chebi fb="0" ids="52726">proteasome inhibitors</z:chebi>, MG-132 and <z:chebi fb="0" ids="52717">PS-341</z:chebi> (<z:chebi fb="0" ids="52717">bortezomib</z:chebi>, <z:chebi fb="0" ids="52717">Velcade</z:chebi>), in primary CLL cells and the Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell line, BJAB, is associated with up-regulation of TRAIL and its <z:hpo ids='HP_0011420'>death</z:hpo> receptors, DR4 and DR5 </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, FLICE-like inhibitory protein (c-FLIP) protein is decreased </plain></SENT>
<SENT sid="4" pm="."><plain>MG-132 treatment increases binding of DR5 to the adaptor protein FADD, and causes caspase-8 activation and cleavage of pro-apoptotic BID </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, DR4:Fc or blockage of DR4 and DR5 expression using <z:chebi fb="40" ids="33697">RNA</z:chebi> interference, which prevents TRAIL apoptotic signaling, blocks <z:chebi fb="0" ids="52726">proteasome inhibitor</z:chebi> induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="6" pm="."><plain>MG-132 also increases <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and DR5 expression in <z:mpath ids='MPATH_458'>normal</z:mpath> B-cells </plain></SENT>
<SENT sid="7" pm="."><plain>However, when the <z:chebi fb="0" ids="52726">proteasome inhibitors</z:chebi> are combined with TRAIL or TRAIL receptor activating antibodies the amount of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> is increased in CLL cells but not in <z:mpath ids='MPATH_458'>normal</z:mpath> B cells </plain></SENT>
<SENT sid="8" pm="."><plain>Thus, activation of the TRAIL apoptotic pathway contributes to <z:chebi fb="0" ids="52726">proteasome inhibitor</z:chebi> induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in CLL cells </plain></SENT>
</text></document>